Clinical Trial Update: Intravenous And Oral Casopitant (GW679769) For The Prevention Of Chemotherapy Induced Nausea And Vomiting [Phase 3]

View source ↗

Summary

A Phase 3 trial evaluating intravenous and oral casopitant for prevention of chemotherapy-induced nausea and vomiting has completed.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Chemotherapy-induced Nausea and Vomiting

Drugs mentioned

• casopitant (casopitant)

Snippet

Sponsor: GlaxoSmithKline | Conditions: Vomiting, Nausea | Phase 3 | Status: COMPLETED